Evogene (TSE:EVGN – Free Report) had its target price cut by Desjardins from C$4.00 to C$3.00 in a research note published on Tuesday,BayStreet.CA reports. They currently have a buy rating on the stock.
Separately, Ventum Financial reduced their price objective on shares of Evogene from C$4.00 to C$3.00 in a research note on Friday, November 22nd.
Get Our Latest Stock Analysis on Evogene
Evogene Price Performance
About Evogene
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
Featured Stories
- Five stocks we like better than Evogene
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- How to Find Undervalued Stocks
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- Which Wall Street Analysts are the Most Accurate?
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
